CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets
Cash	$ 15,721,128	$ 3,551,832
Prepaid drug product for testing	141,345	51,364
Other current assets	171,563	64,117
Total current assets	16,034,036	3,667,313
Other assets
Technology licenses - related party	2,500,374	2,500,374
Less Accumulated Amortization	(1,169,168)	(1,088,856)
Intangible Assets, Net (Excluding Goodwill), Total	1,331,206	1,411,518
TOTAL ASSETS	17,365,242	5,078,831
Current liabilities
Accounts payable	78,915	76,109
Accounts payable - related party	3,213	0
Accrued expense	149,341	66,739
Accrued expense - related party	52,050	52,050
Accrued license payments - related party	50,000	100,000
Total current liabilities	333,519	294,898
Long term debt	0	0
TOTAL LIABILITIES	333,519	294,898
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding		0
Common Stock, $.001 par value, 200,000,000 shares authorized 89,237,872 and 84,237,872 shares issued and outstanding as of 6/30/14 and 12/31/13, respectively	89,238	84,238
Additional paid in capital	34,113,436	20,096,991
Accumulated deficit during development stage	(17,170,951)	(15,397,296)
Total shareholders' equity	17,031,723	4,783,933
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 17,365,242	$ 5,078,831